GlassScriptPhysician profile
Timothy James Corey
NPI 1831270800
$782.44
in general payments reported to CMS, 2019-2025
15 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.06 · 2020: $14.83 · 2023: $208 · 2024: $281 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $234.15 | 2023-2025 | Veozah |
| Biogen, INC. | $140.65 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $91.18 | 2023-2025 | Myfembree |
| Shield Therapeutics INC | $67.98 | 2024-2025 | |
| Medtronic, INC. | $45.04 | 2023 | V-Loc 180 |
| Bayer Healthcare Pharmaceuticals INC. | $36.54 | 2019-2024 | |
| Exeltis, USA INC. | $25.67 | 2023 | Slynd |
| Smith+Nephew, INC. | $22.58 | 2024 | Pico 7 |
| Hologic Sales and Service, LLC | $20.48 | 2025 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Pacira Pharmaceuticals Incorporated | $18.61 | 2025 | Exparel |
| Agile Therapeutics, INC. | $17.91 | 2023 | Twirla |
| Olympus America INC. | $16.82 | 2024 | Olympus |
| Merck Sharp & Dohme LLC | $15.30 | 2024 | Gardasil 9, Gardasil |
| Ironshore Pharmaceuticals INC. | $14.83 | 2020 | |
| Mayne Pharma Commercial LLC | $14.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Corey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.